



EUROPEAN UNION  
OF GENERAL PRACTITIONERS/FAMILY PHYSICIANS  
UNION EUROPÉENNE  
DES MÉDECINS OMNIPRATICIENS/MÉDECINS DE FAMILLE



# UEMO

Dr Hermenegildo Marcos

Vice president UEMO

**AEMH-FEMS**

**Berlin**

**May 2024**



# Founded in Paris 1967


by the five member states of the European Economic Community  
(Belgium, France, Germany, the Netherlands, and Italy)



UEMO aims to

- **Promote** the highest standard of training, practice and patient care within the field of general practice/family medicine throughout Europe and defend the role of general practitioners/family physicians in the health system.
- **Represent** general practitioners to European authorities and international organisations.
- **Collaborate** with other European medical groups to strengthen the position of the profession

# Six permanent Working Groups




1. Competencies of GPs in management of complexity - chronic disease
2. Preventive Activities - vaccination, screening
3. Ad Hoc - Speciality recognition, Cross Border Care, Organisational changes
4. E-Health – remote consultations
5. The value of GPs – surveys on workload and scope of practice
6. CME/CPD – accreditation process





# Liaises with and informs other EU bodies

- Stakeholder in European Medicines Agency
- Stakeholder in HTA
- Member of ONE HEALTH POLICY – AMR
- Member of HERA European Health Emergency Preparedness and Response Authority
- Member of Vaccine Coalition



**HTA**



**HERA**



# European Medicines Agency and AntiMicrobial Resistance (EMA) and One Health Network (AMR)



## Benefits of engagement

- Opportunity to bring a family medicine perspective to discussions
- Reminder that GPs/FDs are the major prescribers for all drugs
- GPs/FDs can warn of practical problems
- Ability to warn of adverse events

# European Health Emergency Preparedness and Response Authority (HERA)



- **AIM :**
- to be the dedicated European authority that will strengthen the EU's preparedness and response capability:
  - Addressing serious cross-border health threats.
  - Addressing vulnerabilities and strategic dependencies within the Union related to the development, production, procurement, stockpiling and distribution of medical countermeasures.
  - Contributing to reinforcing the global health emergency preparedness and response architecture.

# European Health Emergency Preparedness and Response Authority (HERA)



## What can GPs actively participate in Hera ?

- to exchange information
- to share their views.
- to receive regular input, views and opinions from all civil society stakeholders.
- to provide the Advisory Forum with observations and assessments
- to support the work of the Advisory Forum and contribute to its informed opinions and conclusions



# HEALTH TECHNOLOGY ASSESSMENT

- **Procedure for assessing** the added value, effectiveness, costs and broader impact of health care interventions including medicines, medical devices and procedures.
- **Considers the evidence** about medical, economic, social and ethical aspects in relation to the use of health technology.
- **The objective of HTA** is to contribute to the promotion of innovation which provides the best results for patients and society.
  - It is an important tool to ensure the appropriate application and use of health technologies.
  - Look for maximum quality and transparency.





# HTA DOMAINS

## • CLINICAL DOMAINS

- » Health problems and currently used health technologies (e.g. medicines, medical devices, surgical procedures).
- » Description of health technology under assessment.
- » Relative clinical effectiveness.
- » Relative safety.

## • NON-CLINICAL DOMAINS

- » Economic evaluation.
- » Organizational aspects.
- » Social aspects.
- » Legal aspects
- » Ethical aspects.

# TIMELINE



- » 12 January 2025: New oncology medicines and advanced therapy medicinal products will be assessed at EU level.
- » 13 January 2028: Orphan medicinal products to be added to the joint work.
- » 13 January 2030: All new medicines will come under the scope of the regulation.



# ROLE OF THE UEMO

- To assess the impact of treatment in real life
- Opinions and attitudes of GPs facing new technologies in their everyday practice
- **Workforce.** For any introduction of a new device, the commitment of the involved medical staff must be taken into account
- Involvement of experts
- Utility and practical applicability in daily consultation.
- Quaternary prevention.
- Environmental and socioeconomic aspects.
- Innovation providing something new to what already existed previously



# ROLE OF THE UEMO

- First step for discussion with the patient about indication
- Discussion with the patient of tolerance or side effects
- Discussion with the patient and family about ethical problems: surveillance, confidentiality, where are the data, right to die...
- Psychosocial problems: increasing awareness - overinformation and anxiety
- Dangerous devices
- Maintenance staff
- Teaching for users
- Long term side effects
- Duration – replacement.

# EMO work group on health workforce planning



**CEOM**

**CPME**

**EJD**

**EMSA**

**UEMO**

**UEMS**

- More (Enough)
- Better
- Happier

# NEXT ASSEMBLY



Stavanger, Norway, June 7-8



Thank you

